go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

sanofi-aventis

sanofi-aventis
Citywest Business Campus, Dublin 24, Ireland
Telephone: +353 1 4035600
Fax: +353 1 4035687
Medical Information e-mail: IEmedinfo@sanofi-aventis.com


Summary of Product Characteristics last updated on medicines.ie: 04/03/2011
SPC Proctosedyl Ointment

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipients
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Proctosedyl Ointment


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gram of ointment contains 5mg of Hydrocortisone, 5mg of Cinchocaine Hydrochloride, 10mg Aesculin and 10mg Framycetin Sulphate.

Excipients – Contains Wool Fat 10%w/w

For a full lsit of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Ointment.

Yellow white, translucent, homogeneous, ointment.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

In the local management of pain, pruritus and inflammation associated with internal or external haemorrhoids, and such haemorrhoidal complications as fissures, proctitis, perianal eczema, and post1-operative states.


Go to top of the page
4.2 Posology and method of administration

Dosage:

Application to external surface or by means of the cannula into the rectum, twice daily and after each bowel movement. Treatment should last for a week.

Administration:

Topical, Intrarectal and Perianal


Go to top of the page
4.3 Contraindications

1. Use in the presence of untreated infections of viral, tuberculous or fungal origin.

2. Use in patients hypersensitive to the active ingredient or any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

1. Continuous treatment for longer than three weeks should be avoided in patients under the age of three years because of the possibility of adrenocortical suppression and growth retardation.

2. Continuous application without interruption will result in local atrophy of the skin, striae, and superficial vascular dilation.

3. Prolonged use of an anti-infective may result in the development of super-infection due to organisms, including fungi, resistant to that anti-infective.

4. May cause local skin reactions (e.g. contact dermatitis).


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None stated.


Go to top of the page
4.6 Pregnancy and lactation

Animal studies have shown teratogenic effects. To date similar effects have not been shown to occur in man. This product should not be used in pregnancy or lactation unless considered essential by the physician.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

Itching, pain or rash may develop around the back passage.


Go to top of the page
4.9 Overdose

In the rare event of overdosage, supportive and symptomatic therapy is indicated.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

ATC Code: C05A.

A combination of a glucocorticoid, local anaesthetic and antibacterial.


Go to top of the page
5.2 Pharmacokinetic properties

None Stated.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Wool fat (lanolin)

Liquid paraffin

White soft paraffin.


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

Unopened - 3 years

In use shelf life - 4 weeks


Go to top of the page
6.4 Special precautions for storage

Do not store above 25ºC.


Go to top of the page
6.5 Nature and contents of container

Aluminium tubes internally lacquered with cannula treatment. Pack sizes are 15g and 30g. Each tube is accompanied by a cannula attachment.

Not all pack sizes are marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

sanofi-aventis Ireland Ltd.,.

Citywest Business Campus

Dublin 24


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 540/62/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

1st April 1978/25th November 2009.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

September 2010



Link to this document from your website:
http://www.medicines.ie/medicine/2738/SPC/Proctosedyl+Ointment/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Legal Categories

 
   Product subject to medical
prescription which may not
be renewed (A)
   Product subject to medical
prescription which may
be renewed (B)
   Product subject to
restricted prescription
(C)
   Supply through
general sale
   Supply through
pharmacy only

Active Ingredients

 
   Hydrocortisone
   Framycetin Sulphate
   Cinchocaine hydrochloride
   Aesculin

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo